Squarepoint Ops LLC Sells 8,151 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Squarepoint Ops LLC decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 23.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,950 shares of the company’s stock after selling 8,151 shares during the quarter. Squarepoint Ops LLC owned 0.08% of Entrada Therapeutics worth $370,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of TRDA. Vanguard Group Inc. lifted its holdings in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after acquiring an additional 13,742 shares during the period. American Century Companies Inc. lifted its stake in Entrada Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after purchasing an additional 14,838 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Entrada Therapeutics by 27.5% in the 2nd quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock valued at $940,000 after purchasing an additional 14,220 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Entrada Therapeutics during the 2nd quarter worth $636,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Stock Down 2.2 %

Shares of TRDA stock opened at $15.81 on Friday. Entrada Therapeutics, Inc. has a twelve month low of $10.75 and a twelve month high of $18.17. The stock’s fifty day simple moving average is $15.64 and its 200 day simple moving average is $15.04. The firm has a market capitalization of $588.13 million, a P/E ratio of 25.10 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The company had revenue of $94.69 million for the quarter, compared to analysts’ expectations of $55.00 million. As a group, equities research analysts expect that Entrada Therapeutics, Inc. will post 0.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on TRDA shares. Oppenheimer reiterated an “outperform” rating and issued a $25.00 target price on shares of Entrada Therapeutics in a research report on Monday, August 26th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 14th.

Insider Buying and Selling at Entrada Therapeutics

In related news, CEO Dipal Doshi sold 1,600 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.81, for a total value of $28,496.00. Following the sale, the chief executive officer now owns 334,475 shares of the company’s stock, valued at $5,956,999.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Nathan J. Dowden sold 1,904 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.07, for a total value of $28,693.28. Following the transaction, the chief operating officer now owns 125,996 shares in the company, valued at approximately $1,898,759.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Dipal Doshi sold 1,600 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.81, for a total transaction of $28,496.00. Following the completion of the sale, the chief executive officer now directly owns 334,475 shares in the company, valued at approximately $5,956,999.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,825 shares of company stock worth $185,127. 7.58% of the stock is currently owned by company insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.